Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,254,426

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

Pre-Market: $780.49 +4.11 (0.53%) 8:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Wall Street Set to Post Fifth Winning Month Amid Volatility

Wall Street is likely to record the fifth consecutive winning month despite volatility.

Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca

AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.

Zacks Investment Ideas feature highlights: Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics

Apple, Alphabet, Eli Lilly, Novo Nordisk and Viking Therapeutics have been highlighted in this Investment Ideas article.

Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing

Eli Lilly (LLY) closed the most recent trading day at $772.78, moving +1.33% from the previous trading session.

Andrew Rocco headshot

Time to be "Overweight" Viking Therapeutics

A rising obesity rate and the desire for a quick fix are driving the burgeoning weight loss industry. Stock Strategist Andrew Rocco explains why VKTX stands to benefit the most.

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More

AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.

Amazon (AMZN) Boosts Pharmacy Efforts With Lilly's Partnership

Amazon (AMZN) teams up with Lilly to deliver drug prescriptions that are sent to the latter's direct-to-consumer service, LillyDirect.

Lilly (LLY) Partners Amazon to Deliver Drugs Like Zepbound

Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.

Eli Lilly (LLY) Ascends While Market Falls: Some Facts to Note

Eli Lilly (LLY) reachead $757.84 at the closing of the latest trading day, reflecting a +0.38% change compared to its last close.

The Zacks Analyst Blog Highlights Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly

Nvidia, Constellation Energy, Meta Platforms, Advanced Micro Devices and Eli Lilly are part of the Zacks top Analyst Blog.

Novo Nordisk's (NVO) Wegovy Gets FDA Nod to Reduce Heart Risk

Novo Nordisk (NVO) announces FDA approval of its application seeking label expansion for Wegovy to reduce the risks of major adverse cardiovascular events.

Lilly (LLY) Stock Down as FDA Delays Decision on Donanemab

The FDA decision on Eli Lilly's (LLY) Alzheimer's candidate, donanemab, was expected in the first quarter of 2024, which has now been delayed.

Sweta Killa headshot

S&P 500 Soars to New Highs: 5 Best Stocks YTD

The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.

Novo Nordisk (NVO) Up on Upbeat Data From New Obesity Pill Study

Novo Nordisk (NVO) stock rises as it presents encouraging efficacy data on a new investigational oral obesity pill, amycretin, at its Capital Markets Day.

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Viking (VKTX) Stock Down on Novo Nordisk's Obesity Pill Data

Viking Therapeutics (VKTX) falls as VK2735's placebo-adjusted mean weight loss after 13 weeks of treatment in a phase II study appears similar to Novo Nordisk's amycretin in a phase I study.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Zacks Market Edge Highlights: NVDA, DELL, LLY, CMG and CAVA

NVDA, DELL, LLY, CMG and CAVA have been highlighted in this Market Edge article.

Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tracey Ryniec headshot

Should You Buy Red-Hot Stocks Now or Wait?

After a mesmerizing rally to start 2024, is it too late to buy the hottest stocks?